Literature DB >> 8144239

Asbestos exposure according to different exposure indices among Finnish lung cancer patients.

S Vilkman1, A Lahdensuo, J Mattila, A Tossavainen, T Tuomi.   

Abstract

During a 6-month period all lung cancer patients in a university hospital chest clinic were investigated for asbestos exposure by means of personal interview, bronchoalveolar lavage (BAL), roentgenograms, lung function testing, histology and measurement of fibre concentrations in lung tissue samples using scanning electron microscopy (SEM). About one-third of the patients (33%) were classified as having been exposed to asbestos on the basis of the interview. BAL was performed and AB counts were done in 51 patients. Fourteen (27%) BAL specimens had AB counts of 1 or more AB/ml, which is the conventional limit for non-trivial asbestos exposure. For a subgroup of 25 operated lung cancer patients fibre analysis was also available. In six cases (30%) the asbestos-containing samples had asbestos fibre concentrations equal to or more than 1 million fibres/g dry lung. In eight (32%) of the operated lung cancer patients histopathologically confirmed fibrosis was seen; five of these patients were in the two highest exposure classes. Pleural plaques on X-ray films were seen in six (24%) of the operated cases. With each indicator of exposure about 30% of lung cancer patients were found to have been exposed, confirming the "one-third rule"; however, when all the information was collated there were three cases (12%) in which exposure was most obvious according to the different parameters used in this study. In these three cases the cancer could well be attributed to asbestos. Anthophyllite was present in all asbestos-containing samples and anthophyllite was the main fibre type in 61% of these samples.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8144239     DOI: 10.1007/bf00381202

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  18 in total

1.  A pathological study of emphysema of the lungs with chronic bronchitis.

Authors:  B E HEARD
Journal:  Thorax       Date:  1958-06       Impact factor: 9.139

Review 2.  Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group.

Authors: 
Journal:  Eur Respir J       Date:  1989-06       Impact factor: 16.671

3.  Mineral fiber concentration in lung tissue of mesothelioma patients in Finland.

Authors:  T Tuomi; M Segerberg-Konttinen; L Tammilehto; A Tossavainen; E Vanhala
Journal:  Am J Ind Med       Date:  1989       Impact factor: 2.214

4.  A case-referent study of lung cancer, occupational exposures and smoking. II. Role of asbestos exposure.

Authors:  H Kjuus; R Skjaerven; S Langård; J T Lien; T Aamodt
Journal:  Scand J Work Environ Health       Date:  1986-06       Impact factor: 5.024

Review 5.  Asbestos-induced diseases: clinical perspectives.

Authors:  E D Bateman; S R Benatar
Journal:  Q J Med       Date:  1987-03

6.  Fibres and asbestos bodies in bronchoalveolar lavage fluids of asbestos sprayers.

Authors:  T Tuomi; P Oksa; S Anttila; O Taikina-aho; E Taskinen; A Karjalainen; P Tukiainen
Journal:  Br J Ind Med       Date:  1992-07

7.  Asbestos exposure among Finnish lung cancer patients: occupational history and fiber concentration in lung tissue.

Authors:  A Karjalainen; S Anttila; L Heikkilä; P Karhunen; H Vainio
Journal:  Am J Ind Med       Date:  1993-03       Impact factor: 2.214

8.  The relationship between lung cancer and asbestos exposure.

Authors:  T Kishimoto; K Okada
Journal:  Chest       Date:  1988-09       Impact factor: 9.410

9.  [Etiological and histological study of 448 cases of lung cancer (author's transl)].

Authors:  P Ruffie; A Hirsch; D Marteau; J Bignon; J Chrétien
Journal:  Ann Med Interne (Paris)       Date:  1981

10.  [Clinical evaluation of primary lung cancer induced by exposure to asbestos].

Authors:  T Kishimoto; T Ono; K Okada; H Ito
Journal:  Gan No Rinsho       Date:  1987-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.